Cargando…
Author Correction: Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer
Autores principales: | Ajimizu, Hitomi, Ozasa, Hiroaki, Sato, Susumu, Funazo, Tomoko, Sakamori, Yuichi, Nomizo, Takashi, Kuninaga, Kiyomitsu, Ogimoto, Tatsuya, Hosoya, Kazutaka, Yamazoe, Masatoshi, Tsuji, Takahiro, Yoshida, Hironori, Itotani, Ryo, Ueno, Kentaro, Kim, Young Hak, Muro, Shigeo, Hirai, Toyohiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9902538/ https://www.ncbi.nlm.nih.gov/pubmed/36747076 http://dx.doi.org/10.1038/s41598-023-29102-0 |
Ejemplares similares
-
Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer
por: Ajimizu, Hitomi, et al.
Publicado: (2021) -
Yes‐associated protein 1 mediates initial cell survival during lorlatinib treatment through AKT signaling in ROS1‐rearranged lung cancer
por: Yamazoe, Masatoshi, et al.
Publicado: (2022) -
CD47 polymorphism for predicting nivolumab benefit in patients with advanced non‑small‑cell lung cancer
por: Ogimoto, Tatsuya, et al.
Publicado: (2023) -
Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series
por: Hashimoto, Kentaro, et al.
Publicado: (2022) -
MCL1 inhibition is effective against a subset of small-cell lung cancer with high MCL1 and low BCL-X(L) expression
por: Yasuda, Yuto, et al.
Publicado: (2020)